Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669147 | 0.92 | PTGER4 (0.38) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 | |
| SCHEMBL5669143 | 0.92 | PTGER4 (0.38) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 | |
| SCHEMBL5654934 | 0.89 | PTGER4 (0.48) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 | |
| SCHEMBL5653677 | 0.89 | TAS1R3 (0.43) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 | |
| SCHEMBL5654371 | 0.88 | TAS1R3 (0.42) | TAS1R3TAS1R1PTGER4RAB9AMCHR1 | |
| SCHEMBL5739747 | 0.88 | PTGER4 (0.42) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 | |
| SCHEMBL5652300 | 0.86 | PIN1 (0.42) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 | |
| SCHEMBL5652241 | 0.83 | SIRT5 (0.40) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL5655940 | 0.82 | PTGER4 (0.47) | TAS1R3TAS1R1PTGER4RAB9AMCHR1 | |
| SCHEMBL5651559 | 0.81 | PTGER4 (0.47) | TAS1R3TAS1R1PTGER4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1697337-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061475-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | TAS1R3 2373/4885TAS1R1 2391/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.